Skip to main navigation
Wave Life Sciences logo
  • Patients & Families
  • Investors
  • Careers
  • Follow Us
    • X X
    • LinkedIn LinkedIn
    • Glassdoor Glassdoor
  • Company
    • Leadership Team
    • DEI
    • Corporate Responsibility
    • Contact Us
  • Science
    • PRISM™ Platform
    • Publications
    • Collaborations
    • Manufacturing
  • Pipeline
    • R&D Pipeline
    • Lead Programs
  • News
    • Press Releases
  • Home
  • Investors
  • SC 13D/A
  • Company
    • Leadership Team
    • DEI
    • Corporate Responsibility
    • Contact Us
  • Science
    • PRISM™ Platform
    • Publications
    • Collaborations
    • Manufacturing
  • Pipeline
    • R&D Pipeline
    • Lead Programs
  • News
    • Press Releases
line divider for mobile navigation
  • Patients & Families
  • Investors
  • Careers
  • Follow Us
    • X X
    • LinkedIn LinkedIn
    • Glassdoor Glassdoor
Search

Reimagining RNA medicine

  • Menu Icon arrow mobile
  • Overview
  • News
  • Events & Publications
  • SEC Filings
  • Stock Information
  • Analyst Coverage
  • Corporate Governance
  • FAQs

Document Details

Form
SC 13D/A
Filing Date
Nov 12, 2021
Document Date
Nov 12, 2021
Form Description
An amendment to a SC 13D filing
Filing Group
Other
Company
Wave Life Sciences
Issuer
WAVE LIFE SCIENCES LTD.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

Investor Inquiries

Kate Rausch

Investor Relations

617-949-4827

InvestorRelations@wavelifesci.com

Request information

Email Alerts

Sign up here to receive email alerts from Wave Life Sciences.

Sign up
Wave Life Sciences logo
  • Company
  • Leadership Team
  • DEI
  • Corporate Responsibility
  • Contact Us
  • Science
  • PRISM™ Platform
  • Publications
  • Collaborations
  • Manufacturing
  • Pipeline
  • R&D Pipeline
  • Lead Programs
  • News
  • Press Releases

© 2024 Wave Life Sciences. All Rights Reserved.

  • Privacy
  • Terms of use
  • Contact